Calcitonin helps osteoporosis by slowing down the cells that break down bone, reducing bone loss and lowering the risk of fractures. It’s a hormone your body naturally produces to keep calcium levels in check, and a synthetic version (derived from salmon) is available as a nasal spray to treat postmenopausal osteoporosis. That said, calcitonin is not a first-line treatment. It’s considered a last-resort option when stronger medications aren’t suitable.
How Calcitonin Works in Your Body
Your bones are constantly being remodeled. Specialized cells called osteoclasts break down old bone, while osteoblasts build new bone in its place. In osteoporosis, the breakdown outpaces the rebuilding, and bones become weak and porous. Calcitonin targets the osteoclasts directly, suppressing both their activity and their ability to move along bone surfaces. This slows bone breakdown and helps preserve bone density.
The effect works through signaling inside the osteoclast cells. When calcitonin binds to receptors on these cells, it triggers changes in calcium levels within the cell itself, which dampens the cell’s resorption activity. Lab studies have shown that calcitonin not only reduces osteoclast movement but also causes the cells to pull back from bone surfaces entirely, making it a particularly potent inhibitor of bone loss.
Calcitonin vs. Parathyroid Hormone
Calcitonin works as a counterbalance to parathyroid hormone (PTH), the other major hormone involved in calcium regulation. When blood calcium rises, your thyroid gland releases calcitonin to bring levels down, partly by discouraging bone breakdown (which releases calcium into the blood). When blood calcium drops, PTH does the opposite: it ramps up bone resorption to push calcium back into the bloodstream.
The two hormones respond to calcium in mirror-image patterns. Rising calcium stimulates calcitonin and suppresses PTH. Falling calcium does the reverse. Interestingly, not everyone produces a strong calcitonin response to high calcium levels, which is one reason some people may be more vulnerable to bone loss as they age.
How Well It Reduces Fractures
In a prospective study of postmenopausal women with osteoporosis, salmon calcitonin reduced the number of new vertebral fractures by 60% over 24 months compared to baseline. The fracture rate in the calcitonin group was 0.07 per patient per year, versus 0.45 per patient per year in the group receiving only calcium supplements.
These numbers are meaningful, but calcitonin’s fracture-prevention ability is generally considered weaker than what bisphosphonates and other first-line medications can achieve. It also raises bone mineral density less effectively than those alternatives. This is the main reason clinical guidelines from the American Association of Clinical Endocrinologists rank calcitonin as a last-line therapy, behind bisphosphonates, denosumab, and raloxifene.
The Pain Relief Advantage
Where calcitonin stands out is its ability to reduce bone pain, especially after a vertebral compression fracture. This is a type of fracture common in osteoporosis where a weakened vertebra partially collapses, causing severe back pain. Many osteoporosis medications protect against future fractures but do nothing for the pain of one that’s already happened.
Clinical trials have shown significant reductions in pain at rest within the first four weeks of calcitonin treatment, and substantial improvements in pain during movement by week four. One study using calcitonin suppositories found that spinal pain decreased significantly within just five days. This analgesic effect makes calcitonin a preferred option for managing the acute aftermath of an osteoporotic vertebral fracture, even when other drugs handle long-term bone protection.
Why Salmon Calcitonin Is Used
The therapeutic form of calcitonin comes from salmon rather than human sources. Salmon calcitonin has long been considered more potent than the human version, though research suggests this difference may partly be an artifact: human calcitonin tends to clump together in solution, which reduces its effectiveness in lab testing. Regardless of the reason, salmon calcitonin is what’s used in approved medications and has a well-established clinical track record.
How It’s Taken
The standard form is a nasal spray delivering 200 International Units (one spray into one nostril) once daily. An injectable form also exists but is less commonly used for osteoporosis. The nasal spray is simple to administer at home and doesn’t require the empty-stomach timing that some oral osteoporosis medications demand.
Common side effects are mostly local to the nose: runny nose, nosebleed, dryness, crusting, or sinus discomfort. Some people experience back or joint pain, mild nausea, or flushing. These are generally mild and manageable.
Safety Concerns and Current Status
An FDA meta-analysis of 21 clinical trials found a slightly higher rate of malignancies in patients taking calcitonin (4.1%) compared to placebo (2.9%). The data weren’t detailed enough to pinpoint any specific type of cancer, and the FDA has stated there is no conclusive evidence of a causal relationship. Still, the signal was enough to change prescribing recommendations. The updated labeling now specifies that calcitonin should only be used when alternative osteoporosis treatments aren’t suitable, and that treatment should be re-evaluated periodically.
The European Medicines Agency took a stricter stance, recommending against long-term use. In the U.S., calcitonin remains FDA-approved for postmenopausal osteoporosis but sits firmly at the bottom of the treatment hierarchy. For most patients, bisphosphonates or denosumab will be recommended first. Calcitonin is typically reserved for people who can’t tolerate those options, or for short-term pain management after an acute vertebral fracture where its analgesic properties offer a distinct benefit that other osteoporosis drugs don’t provide.